The US government, citing national security authorities, has issued an export control directive to suspend all access to Fable 5 and Mythos 5 by any foreign national, whether inside or outside the United States, including foreign national Anthropic employees. The net effect of this order is that we must abruptly disable Fable 5 and Mythos 5 for all our customers to ensure compliance. Access to all other Claude models is not affected. We apologize for this disruption to our customers. We believe this is a misunderstanding and are working to restore access as soon as possible. Read our full statement: anthropic.com/news/fable-myt…

Tokens will get 90% cheaper every year as models improve and $10k desktop workstations from @dell and @apple, running open source models, drive tokens to “essentially free” Token costs will be looked at like storage and bandwidth costs in a couple of years — which is to say you won’t think about them much.

NEW: @binance ANNOUNCES CANCELLATION OF "BINANCE WALLET SPCXX IPO CAMPAIGN" "DUE TO CIRCUMSTANCES OUTSIDE OF OUR CONTROL, WE ARE UNABLE TO PROCEED WITH THIS CAMPAIGN" SOURCE: binance.com/en/support/annou…

To give you a concrete sense of what we're doing with @Backpack Securities. - Trade stocks on Backpack - Deposit/Withdraw to Solana - Trade on DeFi in your wallet - On/off ramp to your brokerage account Tokenized stocks that are redeemable for the real thing just like a stablecoin. Demo:

Introducing Frontier Traders An exclusive global community for elite firms and traders at the frontier of emerging assets. Members can access rewards across Solana trading venues, dedicated infra, and a voice in shaping Solana’s market structure.

We're excited to join forces with @Castelion to integrate the Blackbeard hypersonic missile with our Marauder MUSV, demonstrating a first-of-its-kind maritime hypersonic launch capability. By pairing autonomous maritime platforms with hypersonics, we are advancing a more distributed and survivable approach to deterrence. Together, we're working to increase capability and capacity by combining autonomous maritime and hypersonic strike capabilities that are more affordable, scalable, and faster to field. With a demonstration targeted for 2027, both companies are investing in the production infrastructure needed to deliver these systems to the warfighter at greater scale and speed. Read more here: medium.com/saronic-technolog…

BREAKING: @Solana continues to surpass all L1 and L2 chains combined in tokenized stock trading volume, extending its lead to 53 consecutive weeks.

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

BREAKING: US strikes have now hit two drinking water tanks in Sirik, southern Iran, cutting off all drinking water in the district, per IRIB. Iran has warned 2 hours ago it will immediately place all regional Gulf energy infrastructure under continuous missile fire, and with this US attack, water desalination infrastructure which the Gulf depends on for over 90%, would specifically become major targets.

Equities are live on Phoenix. NVDA and AAPL are available to trade now — up to 20x leverage, 24/7.

The play is never the move. It's the mind behind it. The World Series of Poker. Now dealt by Solana.

Crypto Executives Urge Congress to Keep Exception for Developers news.bgov.com/bloomberg-gove…

From a 1BR apartment to $10.7M Seed Round lead by @generalcatalyst What was GeoSpy is now Raven. We are turning the physical world into real-time search. 🇺🇸